BDTX
NASDAQ · Biotechnology
Black Diamond Therapeutics I
$2.99
+0.27 (+9.93%)
Open$2.72
Previous Close$2.72
Day High$3.15
Day Low$2.70
52W High$4.94
52W Low$1.77
Volume—
Avg Volume1.00M
Market Cap157.58M
P/E Ratio—
EPS$-0.76
SectorBiotechnology
Analyst Ratings
Strong Buy
15 analysts
Price Target
+1,101.3% upside
Current
$2.99
$2.99
Target
$35.92
$35.92
$30.62
$35.92 avg
$44.24
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 64.09M | 26.85M | 24.30M |
| Net Income | 20.48M | 2.09M | 2.49M |
| Profit Margin | 32.0% | 7.8% | 10.3% |
| EBITDA | 17.06M | 3.87M | 3.57M |
| Free Cash Flow | — | 2.98M | 2.09M |
| Rev Growth | — | +10.3% | +9.4% |
| Debt/Equity | — | 0.41 | 0.35 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |